# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Danielle Antalffy downgrades Treace Medical Concepts (NASDAQ:TMCI) from Buy to Neutral and lowers the price targ...
Treace Medical Concepts reports Q1 EPS loss of $(0.30), sales hit $51.11 million, up 21%. Surge in procedure kits sold due to e...
Morgan Stanley analyst Drew Ranieri downgrades Treace Medical Concepts (NASDAQ:TMCI) from Overweight to Equal-Weight and low...